Gonatopoulos-Pournatzis, Thomas http://orcid.org/0000-0003-2669-2570
Aregger, Michael http://orcid.org/0000-0001-6443-9870
Brown, Kevin R. http://orcid.org/0000-0002-5514-2538
Farhangmehr, Shaghayegh
Braunschweig, Ulrich http://orcid.org/0000-0001-6653-0926
Ward, Henry N. http://orcid.org/0000-0002-9869-9790
Ha, Kevin C. H. http://orcid.org/0000-0001-5746-4365
Weiss, Alexander
Billmann, Maximilian http://orcid.org/0000-0002-6556-9594
Durbic, Tanja
Myers, Chad L. http://orcid.org/0000-0002-1026-5972
Blencowe, Benjamin J.
Moffat, Jason http://orcid.org/0000-0002-5663-8586
Funding for this research was provided by:
Canada First Research Excellence Fund (C1TPA-2016-11, C1TPA-2016-11, C1TPA-2016-11)
European Molecular Biology Organization
Gouvernement du Canada | Canadian Institutes of Health Research (MOP-142375, MOP-142375)
Canada First Research Excellence Fund
Foundation for the National Institutes of Health
Canada First Research Excellence Fund
Canada Excellence Research Chairs, Government of Canada (C1TPA-2016-11)
Genome Canada (OGI-157)
Article History
Received: 26 May 2019
Accepted: 27 January 2020
First Online: 16 March 2020
Competing interests
: A patent application (no. GB 1907733.8) describing the development and applications of CHyMErA, to the University of Toronto and T.G.-P., M.A., K.R.B., S.F., J.M. and B.J.B., is pending.